Temat: "Class I Phosphatidylinositol 3-Kinases" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Autorzy:: Corné J; Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France. .
Le Du F; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Quillien V; Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.; INSERM U1242, University of Rennes, Rennes, France.
Godey F; Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.; INSERM U1242, University of Rennes, Rennes, France.
Robert L; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Bourien H; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Brunot A; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Crouzet L; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Perrin C; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Lefeuvre-Plesse C; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
Diéras V; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.
De la Motte Rouge T; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Aug 27; Vol. 11 (1), pp. 17316. Date of Electronic Publication: 2021 Aug 27.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
Cell-Free Nucleic Acids/*analysis
Class I Phosphatidylinositol 3-Kinases/*genetics
Adolescent ; Base Sequence ; Breast Neoplasms/diagnosis ; Child ; Child, Preschool ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Female ; Humans ; Infant ; Infant, Newborn ; Mutation ; Polymerase Chain Reaction ; Reproducibility of Results ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: PIK3CA mutation enrichment and quantitation from blood and tissue.
Autorzy:: Keraite I; Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, EH14 4AS, UK.; Infection Medicine, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, EH164SB, UK.
Alvarez-Garcia V; Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, EH14 4AS, UK.; Edinburgh Cancer Research Centre, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
Garcia-Murillas I; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.
Beaney M; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.
Turner NC; The Breast Cancer Now Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.; Breast Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.
Bartos C; Edinburgh Cancer Research Centre, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.; Edinburgh Cancer Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK.
Oikonomidou O; Edinburgh Cancer Research Centre, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.; Edinburgh Cancer Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK.
Kersaudy-Kerhoas M; Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, EH14 4AS, UK.; Infection Medicine, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, EH164SB, UK.
Leslie NR; Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, EH14 4AS, UK. .; Institute of Biological Chemistry, Biophysics and Bioengineering, School of Engineering and Physical Sciences, Heriot-Watt University, Edinburgh, EH14 4AS, UK. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Oct 13; Vol. 10 (1), pp. 17082. Date of Electronic Publication: 2020 Oct 13.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms:: Mutation*
Biomarkers, Tumor/*genetics
Breast Neoplasms/*enzymology
Breast Neoplasms/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Biomarkers, Tumor/blood ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/diagnosis ; Cell Line, Tumor ; Class I Phosphatidylinositol 3-Kinases/blood ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Cohort Studies ; DNA Mutational Analysis/methods ; DNA, Neoplasm/genetics ; DNA, Neoplasm/isolation & purification ; Female ; Gene Frequency ; Humans ; MCF-7 Cells ; Real-Time Polymerase Chain Reaction/methods

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Autorzy:: Toppmeyer DL; Department of Medicine, Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Press MF; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2020 Sep; Vol. 9 (18), pp. 6463-6472. Date of Electronic Publication: 2020 Jul 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:: DNA Mutational Analysis*
Mutation*
Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/enzymology ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Clinical Decision-Making ; Female ; Humans ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Precision Medicine ; Predictive Value of Tests ; Prognosis ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients.
Autorzy:: Allouchery V; Department of Medical Oncology, Centre Henri Becquerel, 1 Rue d'Amiens, 76038, Rouen Cedex 1, France. .
Perdrix A; IRON Group, Inserm U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France.; Department of Bio-Pathology, Centre Henri Becquerel, Rouen, France.
Calbrix C; IRON Group, Inserm U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France.; Department of Bio-Pathology, Centre Henri Becquerel, Rouen, France.
Berghian A; Department of Bio-Pathology, Centre Henri Becquerel, Rouen, France.
Lequesne J; Department of Biostatistics, Rouen University Hospital, Rouen, France.
Fontanilles M; Department of Medical Oncology, Centre Henri Becquerel, 1 Rue d'Amiens, 76038, Rouen Cedex 1, France.; IRON Group, Inserm U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France.
Leheurteur M; Department of Medical Oncology, Centre Henri Becquerel, 1 Rue d'Amiens, 76038, Rouen Cedex 1, France.
Etancelin P; Department of Bio-Pathology, Centre Henri Becquerel, Rouen, France.
Sarafan-Vasseur N; IRON Group, Inserm U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France.; Department of Bio-Pathology, Centre Henri Becquerel, Rouen, France.
Di Fiore F; Department of Medical Oncology, Centre Henri Becquerel, 1 Rue d'Amiens, 76038, Rouen Cedex 1, France.; IRON Group, Inserm U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France.; Department of Gastroenterology, Rouen University Hospital, Rouen, France.
Clatot F; Department of Medical Oncology, Centre Henri Becquerel, 1 Rue d'Amiens, 76038, Rouen Cedex 1, France.; IRON Group, Inserm U1245, UNIROUEN, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Normandie Université, Rouen, France.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Dec 15; Vol. 11 (1), pp. 24041. Date of Electronic Publication: 2021 Dec 15.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers, Tumor*
Circulating Tumor DNA*
Mutation*
Class I Phosphatidylinositol 3-Kinases/*genetics
Inflammatory Breast Neoplasms/*diagnosis
Inflammatory Breast Neoplasms/*etiology
Adult ; Aged ; Aged, 80 and over ; DNA Mutational Analysis ; Female ; Humans ; Inflammatory Breast Neoplasms/blood ; Inflammatory Breast Neoplasms/mortality ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; Survival Analysis

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Liquid Biopsy in Breast Cancer: A Focused Review.
Autorzy:: Tay TKY; From the Department of Anatomical Pathology (Tay, Tan), Singapore General Hospital, Singapore.
Tan PH; From the Department of Anatomical Pathology (Tay, Tan), Singapore General Hospital, Singapore.; The Division of Pathology (Tan), Singapore General Hospital, Singapore.; Pokaż więcej
Źródło:: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2021 Jun 01; Vol. 145 (6), pp. 678-686.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
Circulating Tumor DNA/*genetics
Liquid Biopsy/*methods
Neoplastic Cells, Circulating/*metabolism
Breast Neoplasms/diagnosis ; Breast Neoplasms/therapy ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Humans ; Mutation ; Neoplastic Cells, Circulating/pathology ; Outcome Assessment, Health Care/methods

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
Autorzy:: Sharmin S; Department of Microbiology, University of Dhaka, Dhaka, Bangladesh.
Zohura FT; Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh.; Current Affiliation: Internal Medicine OPD, Bangabandhu Sheikh Mujib Medical University Hospital, Dhaka, Bangladesh.
Islam MS; Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh.; Current Affiliation: Department of Biochemistry and Biotechnology, University of Barisal, Barisal, Bangladesh.
Shimonty A; Department of Microbiology, University of Dhaka, Dhaka, Bangladesh.
Khan MA; Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh.; Current Affiliation Department of Mathematics and Natural Sciences, BRAC University, Dhaka, Bangladesh.
Parveen R; Square Hospital, Dhaka, Bangladesh.
Sharmin F; Department of Gynecological Oncology, National Institute of Cancer Research & Hospital, Dhaka, Bangladesh.
Ahsan CR; Department of Microbiology, University of Dhaka, Dhaka, Bangladesh.
Islam ABMMK; Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh.
Yasmin M; Department of Microbiology, University of Dhaka, Dhaka, Bangladesh. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Mar 18; Vol. 21 (1), pp. 289. Date of Electronic Publication: 2021 Mar 18.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Biomarkers, Tumor/*genetics
Uterine Cervical Neoplasms/*genetics
Adult ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Bangladesh ; Biomarkers, Tumor/antagonists & inhibitors ; Cervix Uteri/pathology ; Cervix Uteri/surgery ; Chemotherapy, Adjuvant/methods ; Class I Phosphatidylinositol 3-Kinases/genetics ; Clinical Decision-Making ; Computer Simulation ; DNA Mutational Analysis ; Decision Support Techniques ; ErbB Receptors/genetics ; Female ; Humans ; Hysterectomy ; Middle Aged ; Molecular Targeted Therapy/methods ; Mutation ; Proto-Oncogene Proteins p21(ras)/genetics ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/therapy

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer.
Autorzy:: Song K; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Lu H; The GI Department, Harbin Medical University Cancer Hospital, China.
Jin L; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Wang K; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Guo W; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Zheng H; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Li K; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
He C; The GI Department, Harbin Medical University Cancer Hospital, China.
You T; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Fu Y; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Yang J; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Zhao W; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.
Guo Z; Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, China.; Pokaż więcej
Źródło:: The FEBS journal [FEBS J] 2020 Dec; Vol. 287 (23), pp. 5236-5248. Date of Electronic Publication: 2020 Apr 20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers, Tumor/*metabolism
Cetuximab/*pharmacology
Colorectal Neoplasms/*drug therapy
Drug Resistance, Neoplasm/*genetics
GTP Phosphohydrolases/*metabolism
Gene Expression Regulation, Neoplastic/*drug effects
Membrane Proteins/*metabolism
Proto-Oncogene Proteins p21(ras)/*metabolism
Antineoplastic Agents, Immunological/pharmacology ; Biomarkers, Tumor/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Cohort Studies ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/metabolism ; Colorectal Neoplasms/pathology ; GTP Phosphohydrolases/genetics ; Humans ; Membrane Proteins/genetics ; Mutation ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism ; Proto-Oncogene Proteins p21(ras)/genetics ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Next-generation sequencing for identification of actionable gene mutations in intestinal-type sinonasal adenocarcinoma.
Autorzy:: Sánchez-Fernández P; Department Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Riobello C; Department Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Centro de Investigación Biomédica en Red (CIBER-ONC), Edf. FINBA, N-1 F49, C/ Avenida de Roma s/n, 33011, Oviedo, Spain.
Costales M; Department Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Vivanco B; Department Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Cabal VN; Department Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Centro de Investigación Biomédica en Red (CIBER-ONC), Edf. FINBA, N-1 F49, C/ Avenida de Roma s/n, 33011, Oviedo, Spain.
García-Marín R; Department Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Centro de Investigación Biomédica en Red (CIBER-ONC), Edf. FINBA, N-1 F49, C/ Avenida de Roma s/n, 33011, Oviedo, Spain.
Suárez-Fernández L; Department Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Centro de Investigación Biomédica en Red (CIBER-ONC), Edf. FINBA, N-1 F49, C/ Avenida de Roma s/n, 33011, Oviedo, Spain.
López F; Department Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Cabanillas R; Cabanillas Precision Consulting, Zurich, Switzerland.
Hermsen MA; Department Head and Neck Oncology, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Centro de Investigación Biomédica en Red (CIBER-ONC), Edf. FINBA, N-1 F49, C/ Avenida de Roma s/n, 33011, Oviedo, Spain. .
Llorente JL; Department Otolaryngology, Hospital Universitario Central de Asturias, Oviedo, Spain.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Jan 26; Vol. 11 (1), pp. 2247. Date of Electronic Publication: 2021 Jan 26.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adenocarcinoma/*genetics
Biomarkers, Tumor/*genetics
High-Throughput Nucleotide Sequencing/*methods
Class I Phosphatidylinositol 3-Kinases/genetics ; DNA Repair/genetics ; DNA Repair/physiology ; Genes, BRCA1/physiology ; Humans ; Mutation/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptors, LDL/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Targeted sequencing reveals the somatic mutation landscape in a Swedish breast cancer cohort.
Autorzy:: Mathioudaki A; Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. .
Ljungström V; Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden.
Melin M; Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden.
Arendt ML; Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Nordin J; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Karlsson Å; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Murén E; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Saksena P; Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, Gothenburg, Sweden.
Meadows JRS; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Marinescu VD; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Sjöblom T; Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala, Sweden.
Lindblad-Toh K; Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden. .; Broad Institute of MIT and Harvard, Cambridge, MA, USA. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2020 Nov 09; Vol. 10 (1), pp. 19304. Date of Electronic Publication: 2020 Nov 09.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Gene Expression Regulation, Neoplastic*
Mutation*
Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
APOBEC-1 Deaminase/genetics ; Adult ; Aged ; Aged, 80 and over ; Algorithms ; Animals ; Antigens, CD/genetics ; Cadherin Related Proteins ; Cadherins/genetics ; Cell Cycle Proteins/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Cyclin-Dependent Kinases/genetics ; DNA Mutational Analysis ; DNA-Binding Proteins/genetics ; Dogs ; Female ; Gene Dosage ; Humans ; Middle Aged ; Oligonucleotide Array Sequence Analysis ; Polymorphism, Single Nucleotide ; Proto-Oncogene Proteins/genetics ; Sequence Analysis, DNA ; Sweden/epidemiology ; Transcription Factors/genetics ; Tumor Suppressor Protein p53/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Autorzy:: Xu X; Department of Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Yu Y; Department of Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Shen M; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Liu M; Department of Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Wu S; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Liang L; Department of Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Huang F; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Zhang C; Department of Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China.
Guo W; Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China. .
Liu T; Department of Oncology, Zhongshan Hospital, Fudan University, 180 Feng Lin Road, Shanghai, 200032, PR China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2020 Oct 16; Vol. 20 (1), pp. 1006. Date of Electronic Publication: 2020 Oct 16.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor/*genetics
Cell-Free Nucleic Acids/*genetics
Colorectal Neoplasms/*mortality
Colorectal Neoplasms/*pathology
DNA Mutational Analysis/*methods
Adult ; Aged ; Aged, 80 and over ; China ; Class I Phosphatidylinositol 3-Kinases/genetics ; Colorectal Neoplasms/diagnostic imaging ; Colorectal Neoplasms/genetics ; Female ; GTP Phosphohydrolases/genetics ; High-Throughput Nucleotide Sequencing ; Humans ; Male ; Membrane Proteins/genetics ; Middle Aged ; Neoplasm Metastasis ; Positron Emission Tomography Computed Tomography ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Survival Analysis ; Tumor Burden

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Autorzy:: Lee HK; Department of Thoracic and Cardiovascular Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.
Kwon MJ; Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gwanpyeong-ro 170 beon-gil 22, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea. .
Ra YJ; Department of Thoracic and Cardiovascular Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.
Lee HS; Department of Thoracic and Cardiovascular Surgery, Hallym University Dongtan Sacred Heart Hospital, Hallym University Medical Center, Hwaseong-si, Gyeonggi-do, Republic of Korea.
Kim HS; Department of Thoracic and Cardiovascular Surgery, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Republic of Korea.
Nam ES; Department of Pathology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Cho SJ; Department of Pathology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Republic of Korea.
Park HR; Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gwanpyeong-ro 170 beon-gil 22, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.
Min SK; Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gwanpyeong-ro 170 beon-gil 22, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.
Seo J; Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gwanpyeong-ro 170 beon-gil 22, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.
Choe JY; Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Gwanpyeong-ro 170 beon-gil 22, Dongan-gu, Anyang-si, Gyeonggi-do, 14068, Republic of Korea.
Min KW; Department of Pathology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Seoul, Republic of Korea.
Kang SY; Department of Pathology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Republic of Korea.; Pokaż więcej
Źródło:: Diagnostic pathology [Diagn Pathol] 2020 Oct 14; Vol. 15 (1), pp. 126. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor/*analysis
Class I Phosphatidylinositol 3-Kinases/*genetics
Esophageal Neoplasms/*pathology
Esophageal Squamous Cell Carcinoma/*pathology
Aged ; Aged, 80 and over ; B7-H1 Antigen/metabolism ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/virology ; Esophageal Squamous Cell Carcinoma/genetics ; Esophageal Squamous Cell Carcinoma/virology ; Female ; Humans ; Male ; Microsatellite Instability ; Middle Aged ; Mutation ; Papillomavirus Infections/complications ; Papillomavirus Infections/epidemiology ; Prognosis ; Proto-Oncogene Proteins p21(ras)/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
Autorzy:: Ogasawara A; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Hihara T; Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan.
Shintani D; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Yabuno A; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Ikeda Y; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Tai K; Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan.
Fujiwara K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.
Watanabe K; Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba, Japan.
Hasegawa K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2020 Oct; Vol. 52 (4), pp. 1219-1228. Date of Electronic Publication: 2020 May 06.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor/*blood
Carcinoma, Ovarian Epithelial/*blood
Circulating Tumor DNA/*blood
Neoplasm Recurrence, Local/*epidemiology
Ovarian Neoplasms/*blood
Biomarkers, Tumor/genetics ; Carcinoma, Ovarian Epithelial/genetics ; Carcinoma, Ovarian Epithelial/mortality ; Carcinoma, Ovarian Epithelial/therapy ; Circulating Tumor DNA/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Humans ; Liquid Biopsy/methods ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/genetics ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/therapy ; Preoperative Period ; Prognosis ; Progression-Free Survival ; Proto-Oncogene Proteins p21(ras)/genetics ; Risk Assessment/methods

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.
Autorzy:: Guo S; Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.
Loibl S; German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.
von Minckwitz G; German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.
Darb-Esfahani S; Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Lederer B; German Breast Group, Neu-Isenburg, Charité Universitätsmedizin Berlin, Berlin, Germany.
Denkert C; Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2020 Jul; Vol. 52 (3), pp. 689-696. Date of Electronic Publication: 2020 Feb 04.
Typ publikacji:: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:: Mutation*
Neoadjuvant Therapy*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Carcinoma, Ductal, Breast/*pathology
Class I Phosphatidylinositol 3-Kinases/*genetics
Triple Negative Breast Neoplasms/*pathology
Adult ; Aged ; Bevacizumab/administration & dosage ; Carboplatin/administration & dosage ; Carcinoma, Ductal, Breast/drug therapy ; Carcinoma, Ductal, Breast/genetics ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Polyethylene Glycols/administration & dosage ; Prognosis ; Prospective Studies ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Triple Negative Breast Neoplasms/drug therapy ; Triple Negative Breast Neoplasms/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling.
Autorzy:: De Luca G; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Cardinali B; Breast Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Del Mastro L; Breast Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.; Department of Internal Medicine (Di.M.I.), University of Genova, 16132 Genova, Italy.
Lastraioli S; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Carli F; Department of Pathology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Ferrarini M; DIMES, Anatomy Section, Medical School, University of Genova, 16132 Genova, Italy.
Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, TX 77030, USA.
Garuti A; Department of Internal Medicine (Di.M.I.), University of Genova, 16132 Genova, Italy.
Mazzitelli C; Breast Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Zupo S; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Dono M; Molecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2020 Jun 19; Vol. 21 (12). Date of Electronic Publication: 2020 Jun 19.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
DNA Mutational Analysis/*methods
Neoplastic Cells, Circulating/*chemistry
Cell Line, Tumor ; Class I Phosphatidylinositol 3-Kinases/genetics ; Feasibility Studies ; Female ; High-Throughput Nucleotide Sequencing ; Humans ; MCF-7 Cells ; Precision Medicine ; Proto-Oncogene Proteins p21(ras)/genetics ; Single-Cell Analysis ; Tumor Suppressor Protein p53/genetics

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
Autorzy:: Li X; Department of Pathology, NYU Langone Medical Center, New York, NY, USA.; Present address: Department of Pathology, University of California Irvine, Orange, CA, USA.
Sun K; Department of Pathology, NYU Langone Medical Center, New York, NY, USA.
Liao X; Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA.; Department of Pathology, Mount Sinai Medical Center, New York, NY, USA.
Gao H; Present address: Department of Pathology, University of California Irvine, Orange, CA, USA.
Zhu H; Department of Pathology, Mount Sinai Medical Center, New York, NY, USA.
Xu R; Department of Pathology, NYU Langone Medical Center, New York, NY, USA. .; Department of Pathology, White Plains Hospital, Montefiore Health System, White Plains, NY, USA. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2020 May 08; Vol. 20 (1), pp. 400. Date of Electronic Publication: 2020 May 08.
Typ publikacji:: Journal Article
MeSH Terms:: Mutation*
Mutation Rate*
Adenocarcinoma, Mucinous/*pathology
Biomarkers, Tumor/*genetics
Colorectal Neoplasms/*pathology
Proto-Oncogene Proteins B-raf/*genetics
Proto-Oncogene Proteins p21(ras)/*genetics
Adenocarcinoma, Mucinous/genetics ; Adult ; Aged ; Aged, 80 and over ; Class I Phosphatidylinositol 3-Kinases/genetics ; Colorectal Neoplasms/genetics ; DNA Mutational Analysis ; ErbB Receptors/genetics ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Autorzy:: Takeshita T; Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.
Yamamoto Y; Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.
Yamamoto-Ibusuki M; Department of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
Tomiguchi M; Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.
Sueta A; Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.
Iwase H; Department of Breast and Endocrine Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto 860-8556, Japan.; Pokaż więcej
Źródło:: Cancer biomarkers : section A of Disease markers [Cancer Biomark] 2018; Vol. 22 (2), pp. 345-350.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor*
Circulating Tumor DNA*
Mutation*
Breast Neoplasms/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Estrogen Receptor alpha/*genetics
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/blood ; Breast Neoplasms/diagnosis ; Breast Neoplasms/therapy ; Class I Phosphatidylinositol 3-Kinases/blood ; Combined Modality Therapy ; Estrogen Receptor alpha/blood ; Female ; Humans ; Middle Aged ; Neoplasm Grading ; Neoplasm Metastasis ; Neoplasm Staging ; Receptors, Estrogen

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Autorzy:: Gargano SM; Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Senarathne W; Caris Life Sciences, Phoenix, AZ, USA.
Feldman R; Caris Life Sciences, Phoenix, AZ, USA.
Florento E; Caris Life Sciences, Phoenix, AZ, USA.
Stafford P; Caris Life Sciences, Phoenix, AZ, USA.
Swensen J; Caris Life Sciences, Phoenix, AZ, USA.
Vranic S; College of Medicine, QU Health, Qatar University, Doha, Qatar.
Gatalica Z; Caris Life Sciences, Phoenix, AZ, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2019 Dec; Vol. 8 (17), pp. 7322-7329. Date of Electronic Publication: 2019 Oct 14.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*pharmacology
Biomarkers, Tumor/*antagonists & inhibitors
Carcinoma, Ductal/*drug therapy
Neoplasm Recurrence, Local/*pathology
Salivary Gland Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Androgen Receptor Antagonists/pharmacology ; Androgen Receptor Antagonists/therapeutic use ; Antineoplastic Agents/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; B7-H1 Antigen/metabolism ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Biopsy ; Carcinoma, Ductal/genetics ; Carcinoma, Ductal/immunology ; Carcinoma, Ductal/pathology ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Cohort Studies ; Gene Expression Profiling ; High-Throughput Nucleotide Sequencing ; Humans ; Immunohistochemistry ; MAP Kinase Signaling System/drug effects ; MAP Kinase Signaling System/genetics ; Male ; Middle Aged ; Molecular Targeted Therapy/methods ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/immunology ; Patient Selection ; Protein Isoforms/analysis ; Protein Isoforms/metabolism ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Receptors, Androgen/analysis ; Receptors, Androgen/metabolism ; Salivary Ducts/pathology ; Salivary Gland Neoplasms/drug therapy ; Salivary Gland Neoplasms/genetics ; Salivary Gland Neoplasms/immunology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.
Autorzy:: McCarthy AM; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA. .; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, 833 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104, USA. .
Kumar NP; Harvard T H Chan School of Public Health, Boston, USA.
He W; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Regan S; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Welch M; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Moy B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.
Iafrate AJ; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Chan AT; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA.
Armstrong K; Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, USA.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2020 Apr 23; Vol. 20 (1), pp. 347. Date of Electronic Publication: 2020 Apr 23.
Typ publikacji:: Journal Article
MeSH Terms:: Mutation*
Aspirin/*administration & dosage
Biomarkers, Tumor/*genetics
Breast Neoplasms/*mortality
Class I Phosphatidylinositol 3-Kinases/*genetics
Neoplasm Recurrence, Local/*mortality
Neoplasms, Hormone-Dependent/*mortality
Adult ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Neoplasms, Hormone-Dependent/drug therapy ; Neoplasms, Hormone-Dependent/genetics ; Neoplasms, Hormone-Dependent/secondary ; Prognosis ; Receptor, ErbB-2/metabolism ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Retrospective Studies ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma.
Autorzy:: Leblanc O; Department of Genetics, Curie Institute, PSL Research University, Paris 75005, France.
Vacher S; Department of Genetics, Curie Institute, PSL Research University, Paris 75005, France.
Lecerf C; Department of Drug Development and Innovation (D3i), Curie Institute, PSL Research University, Paris 75005, France.
Jeannot E; Department of Genetics, Curie Institute, PSL Research University, Paris 75005, France.; Department of Pathology, Curie Institute, PSL Research University, Paris 75005, France.
Klijanienko J; Department of Pathology, Curie Institute, PSL Research University, Paris 75005, France.
Berger F; Department of Biostatistics, Curie Institute, PSL Research University, Paris 75005, France.
Hoffmann C; Department of Surgery, Curie Institute, PSL Research University, Paris 75005, France.; INSERM U932 Research Unit, Paris 75005, France.
Calugaru V; Department of Radiotherapy, Curie Institute, PSL Research University, Paris 75005, France.
Badois N; Department of Surgery, Curie Institute, PSL Research University, Paris 75005, France.
Chilles A; Department of Radiotherapy, Curie Institute, PSL Research University, Paris 75005, France.
Lesnik M; Department of Surgery, Curie Institute, PSL Research University, Paris 75005, France.
Krhili S; Department of Surgery, Curie Institute, PSL Research University, Paris 75005, France.
Bieche I; Department of Genetics, Curie Institute, PSL Research University, Paris 75005, France.; EA7331, Faculty of Pharmaceutical and Biological Sciences, Paris Descartes University, Paris 75005, France.
Le Tourneau C; Department of Drug Development and Innovation (D3i), Curie Institute, PSL Research University, Paris 75005, France.; INSERM U900 Research Unit, Curie Institute, Paris 75005, France.
Kamal M; Department of Drug Development and Innovation (D3i), Curie Institute, PSL Research University, Paris 75005, France.; Pokaż więcej
Źródło:: Cancer biology & medicine [Cancer Biol Med] 2020 Feb 15; Vol. 17 (1), pp. 208-217.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers, Tumor/*genetics
Cetuximab/*pharmacology
Drug Resistance, Neoplasm/*genetics
Head and Neck Neoplasms/*drug therapy
Squamous Cell Carcinoma of Head and Neck/*drug therapy
Biomarkers, Tumor/analysis ; Cetuximab/therapeutic use ; Class I Phosphatidylinositol 3-Kinases/genetics ; DNA Mutational Analysis ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Female ; Follow-Up Studies ; Gain of Function Mutation ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/mortality ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Progression-Free Survival ; Proto-Oncogene Proteins p21(ras)/genetics ; Squamous Cell Carcinoma of Head and Neck/genetics ; Squamous Cell Carcinoma of Head and Neck/mortality

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Autorzy:: Chen Z; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Sun T; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada.
Yang Z; The Second Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, China.
Zheng Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Yu R; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada.
Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada.
Yan J; Nanjing Geneseeq Technology Inc., Nanjing, China.
Shao YW; Nanjing Geneseeq Technology Inc., Nanjing, China.; School of Public Health, Nanjing Medical University, Nanjing, China.
Shao X; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Cao W; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Wang X; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.; Pokaż więcej
Źródło:: Molecular genetics & genomic medicine [Mol Genet Genomic Med] 2020 Feb; Vol. 8 (2), pp. e1079. Date of Electronic Publication: 2019 Dec 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Drug Resistance, Neoplasm*
Biomarkers, Tumor/*genetics
Breast Neoplasms/*genetics
Circulating Tumor DNA/*genetics
Adult ; Antineoplastic Agents, Immunological/therapeutic use ; Biomarkers, Tumor/blood ; Breast Neoplasms/blood ; Breast Neoplasms/drug therapy ; Class I Phosphatidylinositol 3-Kinases/genetics ; ErbB Receptors/genetics ; Female ; Histone-Lysine N-Methyltransferase/genetics ; Humans ; Mutation ; Neurofibromin 1/genetics ; Receptor, ErbB-2/genetics ; Trastuzumab/therapeutic use ; Tumor Suppressor Protein p53/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Class I Phosphatidylinositol 3-Kinases"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język